{
    "nctId": "NCT00252811",
    "briefTitle": "A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer",
    "officialTitle": "A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA\u2122) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Estimate the effect of ZD1839 compared with placebo on the change in tumour cell proliferation in patients who have completely ER negative & PgR negative breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically-confirmed ER- and PgR- primary breast cancer\n* Stage T .5 cm, N0-1, M0\n* No previous treatment for breast cancer\n\nExclusion Criteria:\n\n* ALT or AST greater than 2.5 times the ULRR\n* Metastatic disease",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}